FDA Bans Sneaky Drug Importer Jeremy Spencer Brown
Published Date: 2/12/2026
Notice
Summary
Jeremy Spencer Brown is banned for 5 years from importing any drugs into the U.S. because he was convicted of trying to bring in unapproved drugs with the intent to trick people. He didn’t respond to the FDA’s notice, so the ban started on February 12, 2026. He can apply to end this ban anytime, but must follow special rules to keep any private info safe.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 1 costs, 1 mixed.
Five-Year Ban on Drug Importing
Jeremy Spencer Brown is barred for 5 years from importing or offering for import any drug into the United States, effective February 12, 2026. The debarment is based on his February 3, 2025 felony conviction for introduction of unapproved drugs into interstate commerce with intent to defraud or mislead.
Assisting His Imports Is Prohibited
Under section 301(cc) of the FD&C Act, importing or offering for import any drug into the U.S. by, with the assistance of, or at the direction of Jeremy Spencer Brown is a prohibited act as of February 12, 2026. That prohibition makes it unlawful for others to help him import drugs during the debarment period.
How to Seek Removal and Privacy Rules
Mr. Brown may apply to end the debarment at any time by submitting an application (Docket No. FDA-2025-N-0435). Electronic applications submitted to https://www.regulations.gov will be posted publicly unchanged, so confidential information must not be included in electronic filings; to submit confidential information, send a written/paper submission with two copies—one marked "THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION" and one redacted copy for public viewing.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2026-02785 — Agency Information Collection Activities; Submission for OMB Review; Comment Request; Annual Information Return/Report of Employee Benefit Plan
The Department of Labor is asking for public feedback on the yearly report that companies must file about their employee benefit plans. This report helps keep retirement and health plans running smoothly and fairly. Comments are open until March 16, 2026, so plan administrators and anyone interested should speak up now!
Next: 2026-02787 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-United States (U.S.) 2026-2027 Influenza Vaccine Strain Composition
The FDA is hosting a public meeting on March 12, 2026, to decide which flu virus strains will be included in the 2026-2027 flu vaccine. This affects everyone who gets a flu shot, helping make sure the vaccine matches the most common flu types. They’re also asking for your thoughts before March 11, so speak up and help shape next year’s flu protection!